NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

• ClinicalTrials.gov Identifier: NCT05290493
• Recruitment Status: Recruiting
• First Posted: March 22, 2022
• Last Update Posted: March 22, 2022
• Sponsor: Nobias Therapeutics, Inc.
• Information provided by (Responsible Party): Nobias Therapeutics, Inc.

Study Description

Brief Summary:

This is a Phase 2, randomized, placebo-controlled crossover trial to assess the safety and efficacy of NB-001 in children and adolescents with 22q11DS that manifest commonly associated neuropsychiatric conditions.

Condition or disease	Intervention/treatment	Phase
22q11 Deletion Syndrome	Drug: NB-001; Other: Placebo	Phase 2

Detailed Description:

The trial is designed to allow all visits to be conducted via telephone and/or video (i.e., telemedicine) or by home health nurse. An in-person visit is required at Screening unless site or government mandates restrict this due to coronavirus disease-2019 (COVID-19). Other in-person visit(s) may occur, if indicated, based on the Investigator's clinical judgement. Subjects will be screened to confirm eligibility and then randomized in a 1:1 ratio to one of two treatment sequences: NB-001 (active drug product) followed by placebo (treatment sequence A/P) or placebo followed by NB-001 (treatment sequence P/A). During the Double-Blind Treatment Phase of the trial, the subject and/or parent/legal guardian (henceforth, 'parent/guardian') will be contacted at Day 0 to complete baseline symptom scales and will begin dosing with the investigational product (IP; NB-001 or placebo) on the morning of Day 1. Subjects or their parent/guardian will administer the IP twice daily (BID) and will be contacted at Days 0, 1, 14, 28, 42, 49, 50, 63, 77 and 91 to evaluate measures of safety and efficacy, including the completion of symptom scales. In addition, the subject and/or parent/guardian will be contacted at Days 7, 21, 35, 56, 70 and 84 to assess subject safety. Blood samples for pharmacokinetic analysis, 4β-hydroxycholesterol and plasma proline will be collected at multiple timepoints. During the Double-Blind Treatment Phase, subjects will receive IP corresponding with their first treatment assignment for 6 weeks (Treatment Period 1), followed by an intervening wash-out period of 1 week, and then will receive their second treatment assignment for the subsequent 6-week period (Treatment Period 2). All symptom scales will be centrally and/or locally administered. The subject and/or parent/guardian will be contacted for an End of Trial Visit to occur 4 weeks following the last dose of IP to assess safety.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 34 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Intervention Model Description: Subjects will be randomized in a 1:1 ratio to one of two treatment sequences: NB-001 (active drug product) followed by placebo (treatment sequence A/P) or placebo followed by NB-001 (treatment sequence P/A). Subjects will receive IP corresponding with their first treatment assignment for 6 weeks (Treatment Period 1), followed by an intervening wash-out period of 1 week, and then will receive their second treatment assignment for the subsequent 6-week period (Treatment Period 2).
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Masking Description: NB-001 and matching placebo will be supplied to the Investigator or designee in blinded plastic bottles, each containing 40 capsules. Additionally, subject and parent/guardian, the Investigator, clinical trial site personnel, home health nurses, centralized rater(s), and the Sponsor will be blinded to treatment sequence assignment.
• Primary Purpose: Treatment
• Official Title: A Randomized, Placebo-Controlled Crossover Trial to Assess the Safety and Efficacy of NB-001 in Children and Adolescents With 22q11 Deletion Syndrome
• Actual Study Start Date: February 10, 2022
• Estimated Primary Completion Date: December 31, 2022
• Estimated Study Completion Date: January 30, 2023

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: NB-001; Active drug product, NB-001: Two (2) 100 mg capsules will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg.	Drug: NB-001; NB-001 is a non-stimulant activator of multiple metabotropic glutamate receptors (mGluRs).; Other Names: fasoracetam monohydrate; (5R)-5-(pyridine-1-carbonyl)pyrrolidin-2-one monohydrate
Placebo Comparator: Placebo; Placebo: Two (2) capsules (matching NB-001) will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce.	Other: Placebo; Matching, inactive placebo

Outcome Measures

Primary Outcome Measures :

1. Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) Dictionary v.5.0 [ Time Frame: 6 weeks ]

   Clinical and laboratory adverse events (AEs) will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). System Organ Class (SOC) and Preferred Term (PT) will be attached to the clinical database. AE severity will be graded using the CTCAE.

   Summaries (number and percentage of subjects) of TEAEs and TESAEs by SOC and PT will be provided by treatment group. TEAEs will also be summarized by relationship to study drugs and severity. In addition, TEAEs leading to premature discontinuation of study drugs and study, and SAEs leading to death will be summarized and listed.

Secondary Outcome Measures :

1. Change from baseline in Clinical Global Impression Improvement (CGI-I) Scale [ Time Frame: 6 weeks ]
   Responder analyses will be performed for the CGI-I by classifying each subject as a responder or non-responder using an endpoint-specific threshold and computing the response rate in each treatment group. The CGI-S is a 7-point scale where 1=Very much improved and 7=Very much worse.
2. Change from baseline in Clinical Global Impression Severity (CGI-S) Scale [ Time Frame: 6 weeks ]
   Responder analyses will be performed for the CGI-S by classifying each subject as a responder or non-responder using an endpoint-specific threshold and computing the response rate in each treatment group. The CGI-S is a 7-point scale where 1=Normal, Not at all impaired and 7=Among the most extremely impaired patients.
3. Treatment effect of NB-001 on the Pediatric Anxiety Rating Scale (PARS) [ Time Frame: 6 weeks ]
   Treatment effect will be evaluated within the subset of subjects where the symptom of greatest impairment at baseline is anxiety as defined by the Pediatric Anxiety Rating Scale (PARS). A score of >12 on the PARS 5-item total severity score (items 2+3+5+6+7) is indicative of psychiatric symptoms in the clinical range for anxiety disorder, and a score of 10 or 11 is indicative of psychiatric symptoms in the subclinical range for anxiety disorder.
4. Treatment effect of NB-001 on the Attention Deficit Hyperactivity Disorder-Rating Scale (ADHD-RS-5) [ Time Frame: 6 weeks ]
   Treatment effect will be evaluated within the subset of subjects where the symptom of greatest impairment at baseline is attention deficit as assessed by the Attention Deficit Hyperactivity Disorder-Rating Scale (ADHD-RS-5). A score of >6 on the ADHD-RS-5 is indicative of psychiatric symptoms in the clinical range for attention deficit disorder, and a score of 4 or 5 is indicative of psychiatric symptoms in the subclinical range for attention deficit disorder.
5. Treatment effect of NB-001 on the Social Responsiveness Scale, Second Edition (SRS-2) [ Time Frame: 6 weeks ]
   Treatment effect will be evaluated within the subset of subjects where the symptom of greatest impairment at baseline is one or more symptoms in autism spectrum disorder as assessed by the Social Responsiveness Scale, Second Edition (SRS-2). A score of >60 on the SRSTM-2 is indicative of psychiatric symptoms in the clinical range for autism spectrum disorder, and a score of 55-59 is indicative of psychiatric symptoms in the subclinical range for autism spectrum disorder.

Eligibility Criteria

• Ages Eligible for Study: 6 Years to 17 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. The subject has a genotype with a pathologic deletion in the 22q11 region confirmed by documentation (e.g., genetic test results) available at the clinical trial site.
2. The subject is aged 6 to 17 years old, inclusive.

3. The subject has a CGI-S scale score of ≥4 (i.e., moderately, markedly, severely, or among the most extremely ill patients) at Screening. Note that the Severity score of 4 could be from a composite of 2 or more sub-threshold scores.

   And either:

   1. Psychiatric symptoms in the clinical range for at least 1 of 3 disorders, anxiety disorder, ADHD, or ASD, respectively, as demonstrated by score(s) at or above the following numbers on at least 1 of 3 scales:

      • PARS 5-Item Severity Score ≥12 (i.e., sum of items 2+3+5+6+7 ≥12)
      • ADHD-RS-5 Scores of 2 or 3 (i.e., "Often" or "Very Often") on at least 6 questions, with the majority of symptoms related to inattention (common in 22q11DS) rather than hyperactivity (less common in 22q11DS)
      • SRS-2 >60

      OR:

   2. Psychiatric symptoms in the subclinical range for at least 2 of 3 disorders, anxiety disorder, ADHD, and/or ASD, respectively, as demonstrated by scores at or above the following numbers on at least 2 of 3 scales:

      • PARS 5-Item Severity Score of 10 or 11 (i.e., sum of items 2+3+5+6+7=10 or 11)
      • ADHD-RS-5 Scores of 2 or 3 (i.e., "Often" or "Very Often") on 4 or 5 questions, with the majority of symptoms related to inattention (common in 22q11DS) rather than hyperactivity (less common in 22q11DS)
      • SRS-2 of 55-59

4. The subject has adequate renal and hepatic function indicated by:

   • Estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m2 (per the revised Schwartz equation; Fadrowski and Furth 2011, Staples et al. 2010)
   • Serum bilirubin ≤2.5 × upper limit of normal (ULN; unless documented Gilbert's Disease); aspartate aminotransferase and alanine aminotransferase ≤2.5 × ULN
5. If the subject is female and of reproductive potential, she has a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 0.

6. If the subject is of reproductive potential, s/he agrees to abstain from reproductive cell donation, per below, and, if ever heterosexually active, to use dual effective/highly effective contraception (including at least one effective and at least one highly effective contraceptive method; Section 9.2.1) from Screening through the End of Trial Visit.

   • If the subject is female and of reproductive potential, she agrees to abstain from oocyte donation from Screening through the End of Trial Visit.
   • If the subject is male and of reproductive potential, he agrees to abstain from sperm donation from Screening through the End of Trial Visit.
7. The subject's parent/guardian understands the trial procedures and agrees to the subject's participation in the trial, as well as to the parent/guardian trial involvement, as indicated by parent/guardian signature on the informed consent form and, if applicable, subject signature on the subject assent form.

Exclusion Criteria:

1. The subject or parent/guardian is, in the opinion of the Investigator, mentally or legally incapacitated, or has significant emotional problems at the time of Screening or expected emotional problems during the conduct of the trial which would interfere with the conduct of the trial evaluations.
2. The subject has a history of psychotic symptoms, current psychotic symptoms, or a diagnosis of a psychotic disorder based on clinical assessment.
3. The subject has a history of any illness that, in the opinion of the Investigator, might confound the results of the trial or pose an additional risk to the subject by participation in the trial.
4. The subject has clinically significant unstable or uncontrolled endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases.
5. The subject has uncontrolled, active seizure(s), within the 3 months prior to Screening.
6. The subject has known human immunodeficiency virus (HIV), a detectable viral load for hepatitis C, or hepatitis B surface antigen indicative of chronic active infection.
7. The subject is pregnant or is a nursing mother.
8. The subject has suicidal ideation and behavior, based on Investigator assessment of the completed Columbia-Suicide Severity Rating Scale at Screening, or when repeated on Day 0 (if more than 21 days elapse between Screening and Day 1).
9. The subject is currently taking medication(s) at a dose that has not been stable for ≥3 months prior to Day 1 or psychotherapy that has not been stable for ≥3 months prior to Day 1. If the subject is taking medication(s) or receiving psychotherapy, the subject and parent/guardian must agree to continue the intervention(s) at the same dose and frequency through the End of Trial Visit.
10. The subject has received any investigational therapy (i.e., used for a non-approved indication and in the context of a research investigation) <14 days prior to the first dose of NB-001 (i.e., Day 1) or within 5 drug half-lives prior to the first dose of NB-001.
11. The subject uses illicit drugs (e.g., marijuana, amphetamines or cocaine), or has known alcohol or drug abuse or dependence, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (American Psychiatric Association 2013). Medically approved marijuana use, where usage is legal, is allowed; however, the dose and frequency of use should remain stable during trial participation.

Contacts and Locations

Contacts

Contact: Cathi Sciacca; (760) 271-5919; sciacca@nobiastx.com

Contact: Erin Castelloe, MD; (858) 354-6441; castelloe@nobiastx.com

Locations

United States, Pennsylvania

Children's Hospital of Philadelphia (CHOP); Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contact: Panigrahi (Pree) Pratishtha 703-687-7772 panigrahip@chop.edu

Principal Investigator: Madeline Chadehumbe, MD

Sub-Investigator: Raquel Gur, MD, PhD

United States, Washington

Seattle Children's Hospital; Recruiting

Seattle, Washington, United States, 98115

Contact: Maria Benitez-Cortez 206-987-6338 Maria.Benitez-Cortez@seattlechildrens.org

Principal Investigator: Emily Gallagher, MD

Canada, Ontario

The Hospital for Sick Children (SickKids); Not yet recruiting

Toronto, Ontario, Canada, M5G1X8

Contact: Keshini Devakandan (416) 813-7654 keshini.devakandan@sickkids.ca

Principal Investigator: Jacob Vorstman, MD

Sub-Investigator: Nancy Butcher, PhD

Sponsors and Collaborators

Nobias Therapeutics, Inc.

Investigators

• Study Director: Neil Inala; Nobias Therapeutics, Inc.

More Information

• Responsible Party: Nobias Therapeutics, Inc.
• ClinicalTrials.gov Identifier: NCT05290493
• Other Study ID Numbers: NB-001-01
• First Posted: March 22, 2022
• Last Update Posted: March 22, 2022
• Last Verified: March 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Nobias Therapeutics, Inc.:

22q11 Deletion Syndrome; 22q11.2 Deletion Syndrome; 22q11DS; Children and Adolescents

Additional relevant MeSH terms:

DiGeorge Syndrome; 22q11 Deletion Syndrome; Syndrome; Disease; Pathologic Processes; Craniofacial Abnormalities; Musculoskeletal Abnormalities; Musculoskeletal Diseases; Heart Defects, Congenital; Cardiovascular Abnormalities; Cardiovascular Diseases; Heart Diseases; Lymphatic Abnormalities; Lymphatic Diseases; Abnormalities, Multiple; Congenital Abnormalities; Chromosome Disorders; Genetic Diseases, Inborn; Hypoparathyroidism; Parathyroid Diseases; Endocrine System Diseases; 5-((2-(6-Amino-9H-purin-9-yl) ethyl) amino)-1-pentanol; Adenylyl Cyclase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action